Offering genetic testing at the provider’s office at the time of diagnosis effectively increased the number of people with gynecological cancers who underwent testing. That’s…
Gynecological cancer
An experimental immunotherapy known as MOv18 IgE showed promise in overcoming the immune suppression caused by ovarian cancer cells, potentially enabling the immune system…
Corcept Therapeutics is launching a Phase 2 clinical trial to evaluate the safety and efficacy of relacorilant as a triple combination treatment — with…
Adding relacorilant to standard chemotherapy was shown to extend survival among people with platinum-resistant ovarian cancer, meeting the primary endpoint, or goal, of a…
Interim data from a Phase 3 trial failed to show that a combination of nemvaleukin, an experimental immune-modulating therapy, and Keytruda (pembrolizumab) could outperform standard…
Treatment with AbbVie’s Elahere (mirvetuximab soravtansine) reduced the risk of death by 32% in women with difficult-to-treat epithelial ovarian cancer over standard chemotherapy. That’s according…
A Phase 1 clinical trial testing Nikang Therapeutics’ oral therapy NKT3964 in people with certain advanced or metastatic solid tumors, including gynecological cancers,…
In a rare case, a woman in China was found to have fallopian tube cancer in her left tube that had spread to lymph nodes…
Allarity Therapeutics will soon start recruiting patients at several U.S. sites for a new dosing protocol in its Phase 2 trial testing stenoparib…
The U.S. Food and Drug Administration (FDA) has granted fast-track status to CUSP06, Oncusp Therapeutics’ treatment candidate for platinum-resistant ovarian cancer. This designation…
